⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21166121 | 0.76 | — | — | |
| SCHEMBL22833170 | 0.75 | — | — | |
| SCHEMBL724318 | 0.75 | — | — | |
| SCHEMBL4150467 | 0.75 | SMYD2 (0.35) | — | |
| SCHEMBL9899792 | 0.74 | — | — | |
| SCHEMBL30079999 | 0.74 | SCN5A (0.32) | — | |
| SCHEMBL25340611 | 0.72 | BACE1 (0.33) | — | |
| SCHEMBL724317 | 0.71 | — | — | |
| SCHEMBL5757035 | 0.71 | ACACB (0.30) | — | |
| SCHEMBL24524601 | 0.71 | ACACB (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696316-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042740-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4054719-B1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12384750-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| US-11952352-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4334304-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117545748-A | Benzimidazolyl GLP-1GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods of use thereof | 卡莫特医疗有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-4236938-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116600803-A | Macrocyclic urea orexin receptor agonists | 默沙东有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-2822934-A1 | PHENICOL ANTIBACTERIALS | Zoetis LLC (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130237502-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC | 2013-09-12 | — | — | US | disclosed |
| US-20130237502-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC | 2013-09-12 | — | — | US | disclosed |
| US-20130237502-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC | 2013-09-12 | — | — | US | disclosed |
| WO-2013134061-A1 | PHENICOL ANTIBACTERIALS | ZOETIS LLC (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |